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INTRODUCTION
Retinitis pigmentosa (RP) is a hereditary degenerative disease 
of the retina that affects approximately 1 in 4,000 individuals 
worldwide. Rod photoreceptors are predominantly affected, 
and typically patients first experience visual problems under 
moonlight or starlight conditions. As the disease evolves, cone 
photoreceptors also degenerate, peripheral vision deteriorates, 
and patients develop tunnel vision that ultimately progresses to 
result in legal or complete blindness. The age of onset of the dis-
ease varies, but often affected individuals seek medical attention 
during their second decade of life. RP is a genetically heteroge-
neous disease for which all Mendelian forms of inheritance are 
known. In particular, recessively inherited RP is caused by muta-
tions in more than 30 genes and loci (RetNet database; https://
sph.uth.edu/retnet/), most of which account for only a small 
percentage of cases.1 Affected people have been reported in 
diverse ethnic groups worldwide.2–6 Recently, mutations in two 
genes, MAK7,8 and DHDDS,9,10 were found to cause autosomal 
recessive RP (arRP) in patients of Ashkenazi Jewish ancestry, i.e., 
in descendants of Israelites who migrated from the Middle East 
to Central and Eastern Europe during the Middle Ages.
The male germ cell–associated kinase (MAK) is a highly con-
served serine/threonine protein kinase, the expression of which 
is limited to testis11 and retina.12 Four alternative MAK isoforms 
are present in humans; the longer isoform, containing an alterna-
tive 75-bp exon between exons 11 and 12, has a photoreceptor-
specific expression.7,8,13 In mice, Mak regulates photoreceptor 
ciliary length and is crucial for photoreceptor long-term survival; 
for these reasons, Mak−/− animals develop progressive retinal 
degeneration.13 A homozygous 353-bp Alu insertion in exon 9 of 
MAK was originally reported in one isolated RP patient of Jewish 
ancestry and in 20 probands from a cohort of 1,798 unrelated 
arRP cases of mixed ethnicity (~1%). Interestingly, all carriers of 
the mutation reported Jewish ancestry.7 A screen of 1,207 healthy 
individuals of Ashkenazi descent also revealed the presence at a 
relatively high frequency of this Alu insertion in a heterozygous 
state.14 The mutation results in the insertion of 31 incorrect amino 
acids, followed by a premature termination codon; in retinal 
cells derived from patient fibroblasts, this mutation prevents the 
expression of the photoreceptor-specific isoform.7 Clinical mani-
festations in individuals harboring this pathogenic DNA change 
resemble those of autosomal dominant forms of RP linked to 
RP1 mutations; prolonged preservation of the central retina with 
good visual acuity is also a typical feature in these patients.14
DHDDS encodes dehydrodolichyl diphosphate synthase, 
an evolutionarily conserved enzyme participating in the 
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Purpose: Retinitis pigmentosa is a Mendelian disease with a very 
elevated genetic heterogeneity. Most mutations are responsible 
for less than 1% of cases, making molecular diagnosis a multigene 
screening procedure. In this study, we assessed whether direct test-
ing of specific alleles could be a valuable screening approach in cases 
characterized by prevalent founder mutations.
Methods: We screened 275 North American patients with reces-
sive/isolate retinitis pigmentosa for two mutations: an Alu insertion 
in the MAK gene and the p.Lys42Glu missense in the DHDDS gene. 
All patients were unrelated; 35 reported Jewish ancestry and the 
remainder reported mixed ethnicity.
Results: We identified the MAK and DHDDS mutations homo-
zygously in only 2.1% and 0.8%, respectively, of patients of mixed 
 ethnicity, but in 25.7% and 8.6%, respectively, of cases reporting 
Jewish ancestry. Haplotype analyses revealed that inheritance of the 
MAK mutation was attributable to a founder effect.
Conclusion: In contrast to most mutations associated with reti-
nitis pigmentosa—which are, in general, extremely rare—the two 
alleles investigated here cause disease in approximately one-third 
of North American patients reporting Jewish ancestry. Therefore, 
their screening constitutes an alternative procedure to large-scale 
tests for patients belonging to this ethnic group, especially in time-
sensitive situations.
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biosynthesis of dolichol, an essential lipid serving as glycosyl 
moiety carrier for protein N-glycosylation.15 Dolichol is ubiq-
uitously present in human tissues.15,16 In the retina, DHDDS is 
expressed in the inner segment of photoreceptors, where doli-
chol biosynthesis is predicted to happen.9 Recently, a missense 
mutation of a conserved residue (p.Lys42Glu) in DHDDS was 
associated with arRP in a non-consanguineous pedigree of 
Jewish ancestry,10 as well as in 15 other unrelated families of 
Ashkenazi descent, corresponding to a prevalence of ~10% in 
the latter ethnic group.9 Clinically, patients presented with the 
classical form of the disease, with symptoms starting during 
the second decade of life. Unlike patients with the MAK muta-
tion, acuity was reduced to 20/200 in young adulthood. In most 
cases, computerized electroretinography (ERG) responses were 
reported as not detectable as tested.9 The p.Lys42Glu mutation 
has been reported to be an Ashkenazi-specific founder muta-
tion, and it is very rare in other populations.9
In this study, we ascertained the prevalence of these MAK and 
DHDDS mutations in a cohort of North American patients of 
Jewish ancestry and compared it with that from cases of mixed 
ethnicity. Clinical findings are also described.
MATeRIALs AND MeTHODs
Patients
This research was performed in accordance with the tenets 
of the Declaration of Helsinki and was approved by the insti-
tutional review boards of the University of Lausanne and of 
Harvard Medical School and the Massachusetts Eye and Ear 
Infirmary, where the blood was collected and the patients were 
followed. Written informed consent was obtained from patients 
who participated in the study before they donated 10–30 ml of 
their blood for research. Ancestry/ethnic origins of patients 
were self-reported.
DNA from peripheral blood leukocytes was extracted from 
35 unrelated North American RP patients of Jewish ancestry 
and from 240 North American RP patients of mixed ethnic-
ity. These patients had a family history indicative of a recessive 
form of inheritance and they were previously screened for a 
variety of known RP genes. Patients were clinically evaluated 
with an ophthalmologic examination, including Goldmann 
visual field testing and ERGs.17
Genetic analyses
Mutational screening was performed by PCR, followed by 
Sanger sequencing. Primer sequences were either designed using 
Primer3 software or selected from previous literature.9 Primer 
sequences were: 5′-TACCGCCCATTTTTGTTCAT-3′ (MAK 
intron 8, forward); 5′-ACTGAGAACTGTTACTGTGAG-3′ 
(MAK intron 9, reverse); 5′-TCCCTGAAGAATATGAGA 
CCTGT-3′ (DHDDS exon 2 forward); and 5′-CAAACTCAG 
AGCCTGGTTTTCTA-3′ (DHDDS exon 2, reverse). PCR 
amplification was performed in a 25-μl reaction containing 
20 ng genomic DNA, 1x GoTaq buffer, 1.2 mM MgCl2, 0.1 mM 
dNTPs, 0.4 μM of each primer, and 0.01 U/μl of GoTaq poly-
merase (Promega, Madison, WI). Amplification conditions Ta
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were as follows: an initial step at 95 °C for 2 minutes, followed 
by 35 cycles of denaturation at 94 °C for 30 seconds, anneal-
ing at 56 °C (MAK) or 58 °C (DHDDS) for 30 seconds, and 
extension at 72 °C for 1 minute. Before the end of the reac-
tion, a final extension step at 72 °C for 5 minutes was per-
formed. After purification of the PCR product (ExoSAP-IT, 
USB, Santa Clara, CA), the sequencing reaction was performed 
by Sanger sequencing using 3.2 µM of sequencing primers 
(5′-CACTGAGTCATAAAAGTGGT-3′ MAK and 5′-TCCCT 
GAAGAATATGAGACCTGT-3′ DHDDS) and 0.5 µl of BigDye 
Terminator v1.1 (Applied Biosystems, Foster City, CA). The 
sequencing products were then run on an ABI-3130 XLS 
sequencer (Applied Biosystems).
Because the PCR protocol to detect the Alu inser-
tion in MAK could lead to the preferential amplification 
of one allele, we designed additional primers spanning the 
Alu insertion site for the wild-type and the mutant allele 
(5′-CGAAATGGAGAATCTTTTTTCCT-3′ wild-type and 
5′-GAAAAAAGGAGGCCGGGCGCGGT-3′ mutant). Nested 
PCR was performed using primers for the wild-type or mutant 
allele in combination with primers used for amplification 
of exon 9. PCR conditions were the same as reported here, 
except that amplification cycles were reduced to 13 or to 15, 
respectively.
Haplotype analysis of patients harboring the Alu inser-
tion in MAK was performed by sequencing eight polymor-
phic markers around the insertion site using PCR conditions 
reported here and primer pairs listed in Supplementary 
Table S1 online.
Sequencing of the two hypervariable regions in mitochon-
drial DNA of patients carrying either the DHDDS or the 
MAK mutation was accomplished by PCR amplification fol-
lowed by Sanger sequencing using primers reported in previ-
ous literature18 (5′-TCAAATGGGCCTGTCCTTGTAG-3′ and 
5′-GGGTGATGTGAGCCCGTCTA-3′) and identical PCR con-
ditions as reported here, except that annealing of the primers was 
performed at 65 °C. Sanger sequencing was performed using 3.2 µM 
of sequencing primers 5′-TCAAATGGGCCTGTCCTTGTAG-3′ 
and 5′-CTGTATCCGACATCTGGTTCCT-3′.
ResULTs
Genetic analysis
Screening of 275 unrelated patients revealed the presence of 14 
cases harboring the Alu insertion in exon 9 of MAK in a homo-
zygous state. Of these, nine belonged to a subgroup of 35 arRP 
patients of Jewish ancestry, which corresponds to a prevalence 
of 25.7% within this ethnic group. The remaining five belonged 
to a subgroup of arRP patients of mixed ethnicity (prevalence 
= 5/240, or 2.1%). However, the latter positive individuals all 
reported East European origin and therefore were compatible 
with a possible Ashkenazi Jewish descent. No heterozygotes 
were found.
We ascertained the haplotype associated with the Alu inser-
tion by sequencing eight polymorphic single-nucleotide poly-
morphisms (SNPs) with minor allele frequency of 0.01 to 0.30 
and encompassing the insertion site. All patients harboring 
the insertion shared a homozygous haplotype for five mark-
ers around the mutation, confirming that the mutation was the 
result of a founder effect (Table 1).
After the screening of the same cohort of 275 patients for 
p.Lys42Glu in DHDDS, we found five patients carrying the 
mutation in a homozygous state. Three reported Jewish ances-
try (prevalence = 3/35, or 8.6%), whereas two reported Russian 
or Eastern European ancestry, which again was compatible with 
a possible Ashkenazi Jewish origin. One patient (121–423) car-
ried p.Lys42Glu heterozygously.
Investigation of mitochondrial DNA haplotypes revealed that 
three patients harboring the MAK insertion (003-033, 121–847, 
and 121–470) and one patient with the DHDDS mutation 
(121–463) belonged to the mitochondrial haplogroup K1a1b1a 
(markers 16224, 16234, 16311, 16519, 73, 114, 263). One MAK-
positive patient (003–321) and one DHDDS-positive patient 
Figure 1 Fundus photos of left eyes of patients with either MAK (top) or DHDDS (bottom) mutations.
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(003-015) belonged to the haplogroup N1b2 (markers 16145, 
16176A, 16223, 16390, 16519, 73, 152, 263).
Clinical assessment
The self-reported mean age of onset of night blindness in 
patients with the Alu insertion in MAK was 29 years (n = 14; 
range, 18–41 years at first visit), and age of onset of visual 
field loss was 30 years (n = 14; range, 12–51 years) (Table 2). 
In agreement with what was previously observed by Stone et 
al.,14 patients carrying the Alu insertion in MAK had preserved 
visual acuity in at least one eye at their initial visit. In half of 
these patients visual field areas were reduced by 50% or more 
compared with lower normal values. Most had 30-Hz cone 
ERGs that were reduced 95% below normal.
Self-reported mean age of onset of night blindness in patients 
with the DHDDS mutation was 28 years (n = 5; range, 21–32 
years at first visit), and onset of visual field loss was 29 years (n 
= 5; range, 16–33 years at first visit) (Table 2). In their mid 30s, 
most had visual field areas reduced by 50% or more compared 
with control individuals. Their 30-Hz cone ERGs were reduced 
more than 90% below normal. These patients were not exam-
ined later in life to ascertain whether visual acuity was retained.
Patients with either MAK or DHDDS mutations in practically 
all cases presented with posterior subcapsular cataracts, and all 
showed intraretinal pigment in a bone spicule configuration in 
the periphery, typical of RP (Figure 1).
DIsCUssION
There is a growing list of genes that have been shown to be 
responsible for a high percentage of cases of recessive reti-
nal degenerations in individuals of Ashkenazi descent (e.g., 
CLRN119 and PCDH1520). In our screen of North American 
arRP patients of Jewish ancestry, we found a prevalence of 
~26% for the Alu insertion in MAK, and of ~9% for the 
missense mutation in DHDDS. Despite all known retinal 
degeneration genes can now be collectively queried by DNA 
capture panels and next-generation sequencing (NGS), these 
elevated prevalence figures may justify the screening of these 
two mutations in patients of Jewish ancestry, particularly for 
time-sensitive cases or for individuals whose health insur-
ance does not cover large-scale tests. Furthermore, the Alu 
insertion in MAK may not be recognizable by NGS tech-
niques,7 highlighting the value of simple PCR-based proce-
dures to detect this mutation, either as a prescreening test or 
to retrospectively query samples that are seemingly negative 
to NGS approaches.
Haplotype analysis in patients carrying the Alu insertion in 
MAK showed a shared homozygous region of five polymorphic 
markers, suggesting that this is a founder mutation in the Jewish 
population. This also indicates that, most likely, the individu-
als reporting mixed ethnicity who were also found to harbor 
the mutation had ancestors from this ethnic group. To further 
investigate whether patients carrying one of the two muta-
tions were indeed of Ashkenazi descent, we sequenced the two 
hypervariable regions of the mitochondrial genome. We found 
that six patients carried the K1a1b1a and N1b2 haplogroups, 
which are both enriched in Ashkenazi Jews but are very rare 
in other populations.21–23 The remainder had haplogroups that 
were compatible with, but not exclusive of, Ashkenazi descent. 
The presence of the N1b2 genotype in a patient reporting mixed 
ethnicity (003-321) provides an additional level of support to 
the notion that homozoygosity of MAK mutations is attribut-
able to a founder effect.
From a clinical standpoint, all patients had signs of typical 
RP and no significant differences could be noted in general 
between patients with MAK vs. DHDDS mutations. However, 
three individuals with the MAK mutation presented ocu-
lar manifestations that differed from the average of all other 
patients. Patient 121–184 showed more severe loss of retinal 
function with a substantial reduction of visual field and almost 
unrecordable cone responses. By contrast, patients 003–213 
and 003–033 had ages comparable to that of patient 121–184 
but had milder clinical features, with more preserved visual 
field and larger cone ERGs (Table 2). A possible explanation 
is that these patients harbor additional variants that, added to 
the effect of the mutation, can modulate the overall phenotype.
Because of the degree of variability in retinal function detected 
by visual field and ERGs in patients of comparable age with the 
DHDDS mutation, the same explanation could apply for this 
mutation as well.
In conclusion, we found that a 353-bp Alu insertion in MAK 
and the p.Lys42Glu mutation in DHDDS are common causes of 
arRP in North American patients of Jewish ancestry. More spe-
cifically, these two mutations alone account for approximately 
one-third of such recessive or isolate cases and therefore should 
be considered primary targets for molecular diagnosis of RP in 
patients within this ethnic group.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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